More importantly, due to the clinical importance of this study, we confirmed that G3BP1 could regulate the key target molecule P53, which has been proven to be a viable therapeutic target for developing drugs to treat inflammation, immunoregulation and cancer. The gene discussed is TP53; the disease is cancer.